版本:
中国

BRIEF-Lexicon Pharmac reports positive late-stage data on diabetes drug

June 9 Lexicon Pharmaceuticals Inc-

* Lexicon Pharmaceuticals reports positive top-line results in phase 3 intandem3 study for sotagliflozin in patients with type 1 diabetes

* Lexicon Pharmaceuticals reports positive top-line results in phase 3 intandem3 study for sotagliflozin in patients with type 1 diabetes

* Lexicon Pharmaceuticals Inc - ‍study met its primary endpoint​

* Sotagliflozin demonstrated a generally well tolerated safety profile during a 24-week treatment period

* Lexicon Pharmaceuticals Inc - sotagliflozin demonstrates statistically significant benefit in primary endpoint

* Lexicon Pharmaceuticals Inc - results support a unique drug profile as an sglt1 and sglt2 inhibitor Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐